SCHEMBL30954086

SCHEMBL30954086

CCOC(=O)c1c(F)c(Cl)cc2c1OCCN2.CCOC(=O)c1c(F)c(Cl)cc2c1OCCN2CCCc1ccc(F)cc1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
ALDH1A1 P00352 2/20 0.34
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
RECQL P46063 1/20 0.33
DGAT1 O75907 1/20 0.33
SOAT1 P35610 1/20 0.33
NAAA Q02083 1/20 0.33
LMNA P02545 1/20 0.33
P2RY12 Q9H244 1/20 0.33
KMT2A Q03164 1/20 0.33
GAA P10253 1/20 0.33
ALOX15 P16050 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
DRD2 P14416 1/20 0.33
CMA1 P23946 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30954159 0.95 MAPT (0.36) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL27434239 0.92 MAPT (0.39) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL30954115 0.88 MAPT (0.36) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL30954117 0.87 HTR4 (0.33) MAPTKDM4EALDH1A1POLBRECQL
SCHEMBL27434123 0.86 MAPT (0.40) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL30954165 0.83 MAPT (0.38) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL27434250 0.80 NAAA (0.42) NAAADRD2
SCHEMBL30954061 0.80 NAAA (0.42) NAAADRD2
SCHEMBL30954084 0.80 NR1H2 (0.36) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL27433652 0.80 NR1H2 (0.36) MAPTKDM4EPKMALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed